29 September 2025
AQSE: EDX
("EDX Medical" or the "Company")
Result of Annual General Meeting
The Annual General Meeting of EDX Medical Group Plc was held at Marcus Beck Library, 3rd Floor, 1 Wimpole Street, London, W1G 0AE on 29 September 2025 at 2:00pm.
All 16 resolutions put to members were passed on a poll. Resolutions 1 to 13 were passed as ordinary resolutions and resolutions 14 to 16 were passed as special resolutions.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
| Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
| Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the year ended 31 March 2025 together with the Directors' reports and auditor's report on those accounts. |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 2 (Ordinary) To accept the Remuneration Committee Report for the financial year ended 31 March 2025, as set out in the Company's Annual Report and Accounts for the year ended 31 March 2025 |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 3 (Ordinary) To accept the Directors' Remuneration Policy as set out in the Company's Annual Report and Accounts for the year ended 31 March 2025 |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 4 (Ordinary) To re-appoint Jason Holt as a director of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 5 (Ordinary) To re-appoint Dr Michael Hudson as a director of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 6 (Ordinary) To re-appoint Professor Sir Christopher Evans as a director of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 7 (Ordinary) To re-appoint Professor Trevor Jones as a director of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 8 (Ordinary) To appoint Martin Walton as a director of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 9 (Ordinary) To re-appoint PKF Littlejohn LLP as auditor of the Company |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 10 (Ordinary) To authorise the Directors to determine the fees payable to the auditor |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 11 (Ordinary) To approve the EDX Medical Group Plc Non-Enterprise Management Incentive Plan |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 12 (Ordinary) To approve the EDX Medical Group Plc Enterprise Management Incentive Plan |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
| Resolution 13 (Ordinary) To authorise the Directors to allot shares in the Company. |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
| Resolution 14 (Special) To disapply statutory pre-emption rights generally. |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
| Resolution 15 (Special) To disapply statuatory pre-emption rights pursuant to an acquisition or other capital investment. |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
| Resolution 16 (Special) To authorise the Company to make market purchases. |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
As at 29 September 2025, there were 372,308,871 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
Contacts:
| EDX Medical Group Plc |
|
| Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301
|
| |
|
| Oberon Capital |
|
| Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
| |
|
| IFC Advisory (Investor Relations) Tim Metcalfe Graham Herring
|
+44 (0) 203 934 6630 |
| Media House International Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
Notes to Editors:
About EDX Medical Group Plc
EDX Medical Group Plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.